Editor’s Note
**Editor’s Note:** Hugel has officially entered the Indian market, unveiling its botulinum toxin product ‘Letybo’ at the Global Aesthetics Summit in Goa. This strategic move taps into India’s rapidly expanding medical aesthetics sector, driven by its massive population and growing middle class.
Global total medical aesthetics company Hugel announced its official entry into the Indian market with its botulinum toxin product ‘Letybo’ at the ‘Global Aesthetics Summit (GAS)’ held in Goa, India, from the 19th to the 21st. India, with a population of approximately 1.5 billion—the world’s largest—and a rapidly growing middle class, is seeing its medical aesthetics market expand. However, the botulinum toxin procedure rate remains low, positioning it as a market with significant growth potential. Hugel plans to establish an early market presence this year, targeting a 9% market share in the Indian aesthetic market.
At the conference, Hugel, together with its local partner Aakaar Medical, engaged in activities to enhance brand awareness and build a network of Key Opinion Leaders (KOLs).
The company plans to sequentially conduct product launch events and hands-on workshops with local distributors until the 24th. Subsequently, it aims to strengthen its brand position in the Indian market by expanding academic exchanges with KOLs, and based on this, expand its business into the Asia-Pacific region.